1. Home
  2. NVAX vs SPRY Comparison

NVAX vs SPRY Comparison

Compare NVAX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.25

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$9.20

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVAX
SPRY
Founded
1987
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.0B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
NVAX
SPRY
Price
$9.25
$9.20
Analyst Decision
Hold
Strong Buy
Analyst Count
9
2
Target Price
$10.78
$35.00
AVG Volume (30 Days)
3.8M
1.1M
Earning Date
04-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
77.26
114.04
EPS
2.53
N/A
Revenue
$682,162,000.00
$89,149,000.00
Revenue This Year
$58.91
N/A
Revenue Next Year
N/A
$119.97
P/E Ratio
$3.68
N/A
Revenue Growth
N/A
297063.34
52 Week Low
$5.01
$6.66
52 Week High
$10.63
$18.63

Technical Indicators

Market Signals
Indicator
NVAX
SPRY
Relative Strength Index (RSI) 58.44 41.60
Support Level $8.01 $8.61
Resistance Level $10.42 $10.44
Average True Range (ATR) 0.55 0.54
MACD 0.01 -0.04
Stochastic Oscillator 79.50 27.23

Price Performance

Historical Comparison
NVAX
SPRY

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: